GlassScriptPhysician profile
Thomas O Mayer
NPI 1104813930
$7,745.23
in general payments reported to CMS, 2019-2025
44 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $639 · 2021: $1,230 · 2022: $1,318 · 2023: $1,453 · 2024: $1,372 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,883 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,883.25 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,261.32 | 2021-2025 | |
| Biogen, INC. | $866.15 | 2019-2025 | Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $622.66 | 2019-2025 | |
| Celgene Corporation | $610.19 | 2021-2025 | Zeposia |
| Emd Serono, INC. | $443.96 | 2019-2025 | Mavenclad |
| Upsher-Smith Laboratories LLC | $294.68 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $288.55 | 2019-2024 | Austedo Xr, Austedo |
| Abbott Laboratories | $229.48 | 2020-2025 | Infinity |
| Neurocrine Biosciences, INC. | $226.42 | 2022-2025 | Ingrezza, Ongentys |
| Tg Therapeutics, INC. | $222.72 | 2023-2025 | |
| Ucb, INC. | $219.51 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Lundbeck LLC | $218.25 | 2020-2025 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $210.90 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $191.72 | 2019-2025 | Ultomiris, Koselugo |
| Pfizer INC. | $151.51 | 2021-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $132.26 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $123.58 | 2020-2021 | |
| Amgen INC. | $119.26 | 2021-2022 | |
| Argenx US, INC. | $97.08 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Harmony Biosciences LLC | $91.12 | 2023-2025 | Wakix |
| Eisai INC. | $84.10 | 2021-2025 | |
| Merz Pharmaceuticals, LLC | $81.84 | 2021-2024 | Xeomin |
| Supernus Pharmaceuticals, INC. | $81.37 | 2021-2023 | Oxtellar Xr |
| Sk Life Science, INC. | $78.13 | 2021-2023 | |
| Lilly USA, LLC | $69.05 | 2020-2025 | Kisunla |
| Biohaven Pharmaceutical Holding Company LTD. | $66.64 | 2022 | |
| Livanova USA, INC. | $65.55 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Nevro Corp. | $61.98 | 2020-2024 | Senza |
| Acorda Therapeutics, INC | $55.76 | 2019-2022 | |
| Genentech USA, INC. | $55.36 | 2019-2024 | Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $51.24 | 2022-2023 | Nuplazid |
| Csl Behring | $50.69 | 2025 | Hizentra |
| Grifols USA, LLC | $46.10 | 2022-2025 | Gamunex-C |
| Avadel Cns Pharmaceuticals, LLC | $45.27 | 2025 | Lumryz |
| Allergan, INC. | $36.97 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.58 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $27.44 | 2021 | |
| Saluda Medical Americas, INC. | $26.99 | 2024 | Evoke |
| Astrazeneca Pharmaceuticals LP | $24.67 | 2024 | Andexxa |
| Amneal Pharmaceuticals LLC | $20.21 | 2025 | Ongentys |
| Medtronic, INC. | $19.93 | 2024 | Percept PC Brainsense |
| Inspire Medical Systems, INC. | $17.28 | 2024 | Inspire |
| Jazz Pharmaceuticals INC. | $15.07 | 2022 | |
| Tanabe Pharma America, INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.